anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
Subjects were randomized to clopidogrel 75 mg daily for 6 weeks. Then immediately transitioned to a placebo daily for 6 weeks.
Physical therapists use many ways to treat joints that do not move well. One way takes 1-2 seconds. Another way may take up to 1 minute. Both stretches seem to work, but we do not know how. Certain changes in the brain and spinal cord may cause joints to become more flexible after these kinds of stretches. Right now, we do not have very much information about how these might work in people who have injured their ankle. This study will find out if changes in the brain cause better flexibility in the ankle joint after different kinds of stretches. In this study, subjects with a certain kind of ankle sprains and limited ankle joint flexibility will be assigned to 1 out of 3 groups. Subjects will not get to choose their groups. The first group will have an ankle stretch that lasts 1-2 seconds. The second group will have a stretch that last 1 minute. The third group will have their foot held without any stretching. We will use a machine to stimulate the brain and spinal cord to find out how these stretches affect the brain and spinal cord. The machine sends a magnetic signal to the brain, and we will measure how much signal gets through to the leg muscles using electrodes on the skin. We also will use 3 flexibility tests to find out how well each stretch worked. One test is with the subject lying on their stomach, and the others are with the subject standing up. To start the study, subjects will get their brain stimulated. They will then get their brain stimulated again one hour later. After the second stimulation, subjects will have their flexibility tested and then get 1 of the 3 treatments. After the treatment, subjects will get a last brain stimulation test and flexibility tests. We think subjects that get a fast stretch will have better brain function and flexibility than subjects that get the slow stretch or no stretch. To test our idea, we will compare how each group did with the brain stimulation and flexibility tests. We will also look at the relationship between brain function and flexibility.
PROBLEM TO BE SOLVED: To obtain a perfume compsn. which is fruity and emits a gorgeous excellent smell by incorporating 4-t-butylcyclohexyl acetate having specified cis-isomer content, solidification point, and acetic acid content into the same. SOLUTION: This compsn. contains 4-t-butylcyclohexyl acetate(BCA) having a cis-isomer content of 90% or higher, a solidification point of -35 deg.C or higher, and an acetic acid content of 50 ppm or lower. Pref., BCA used contains, as impurities, about 500 ppm or lower 4-t-butylcyclohexanol, about 500 ppm or lower 4-t-butylcyclohexene, and about 3,000 ppm or lower cis-3-t-butylcyclohexyl acetate. The compsn. is prepd. by mixing about 0.01-50 wt.% BCA into another known perfume while adjusting the content of p-t-butylphenol to about 500 ppm or lower and the water content to about 1,000 ppm or lower.
From day 7\~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. On the day of ovulation, COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed and the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle. If biochemical pregnancy is not achieved, thawed blastocysts transfer will be performed.
Recurrent ovarian cancer has a dismal prognosis and there is a pressing need to identify more efficient therapies. Ovarian cancer is highly immunogenic and good survival is tightly linked to the presence of tumor-infiltrating T cells and the absence of immunosuppressive immune cells. This anti-tumor immune response might be primed by chemotherapy.

Gemcitabine has immune-modulatory properties in addition to its direct cytotoxic effect in platinum resistant ovarian cancer. Additionally, Peg-Intron allows the full maturation of dendritic cells, thereby enhancing the anti-tumor response. Moreover, the tumor-associated self-antigen p53 is commonly over-expressed in ovarian cancer and can serve as a target for immunotherapy. Therefore, chemo-immunotherapy with gemcitabine and Peg-Intron plus/minus p53 SLP vaccination seems an attractive treatment for recurrent, p53+ ovarian cancer patients.
PURPOSE:To provide the title adhesive which can bond ceramic materials firmly to metallic materials and has excellent biocempatibility, by incorporating a specified filler in a resin component. CONSTITUTION:30-75wt% hydroxyapatite having an average particle size of 0.5-50mum as a filler is added to a resin component consisting of a polymn. initiator, a sensitizer, a polymn. inhibitor, an ultraviolet absorber, a resin or a monomer, etc. to obtain an adhesive 4 for ceramics. A metallic core material 3 is inserted into a hole 2 formed at the central part of a dental root 1 composed of hydroxyapatite buried in an alveolus and the root 1 is bonded to the core material 3 by means of the adhesive 4. A shaft 7 provided at the bottom of a metallic frustoconical support 6 is inserted into a hole 5 formed in the core material 3 and fixed thereto by the adhesive 4. The support 6 is covered with a crown 8 and fixed.
Participants will receive placebo once daily (OD) at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment C) in Period 1 followed by Dose 1 of seltorexant tablets and placebo OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment A) in Period 2 followed by Dose 2 of seltorexant tablets OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment D) in Period 3 followed by zopiclone on Day 1 and Day 8 and placebo from Day 2 to Day 7 OD at bedtime (Treatment B) in Period 4. There will be a washout period of 5 to 21 days between each period.
Because of the increasing adoption of Electronic Medical Record (EMR) systems, the data access of EMR is more and more convenient. However, there still have difficulties in analyzing all the clinical data directly due to a large number of records using the narrative format. In order to perform research smoothly, the process of information extraction is required for translating data in clinical text into available format for analysis and statistic. In medical research, the problem of missing data occurs frequently. It is important to develop the method with better imputation performance in the stability and accuracy. The purposes of this project are to provide the data integration and extraction methods for handling the structured and unstructured data sources in more efficient ways, to provide the validation scheme for facilitating the data reviewing of extracted results produced by information extraction modules, to increase the quality of clinical data by comparing the data from different data sources and correcting data errors and inconsistent, to handle the clinical data with the properties of time series and incompleteness, to increase accuracy of data analysis and increase quality of health care by improving the completeness and correctness of clinical data, to provide flexibility of methods in the platform. In the project, the disease topic is focused on the liver cancer patients' clinical data and we hope the methods in the projects can be extended to handle other diseases by replacing these knowledge models in the future.
The present invention relates to a Chinese medicament for treating spasm of eye and facial muscles and a preparing method thereof, which  belongs to the technical field of medicament. The preparing method is used for achieving the purpose of treating spasm of eye and facial muscles by the Chinese medicament. The present invention has the technical scheme that the Chinese medicament is prepared from scorpion, centipede, antelope horn, spina date seed, tall gastrodia tuber, gambir plant, earthworm, giant typhonium rhizome and silkworm larva, and is prepared into capsules for convenient administration by treating the materials in the steps of proportioning, cleaning, selecting, crushing, sieving, mixing and encapsulating. The Chinese medicament mainly has the functions of hyperactive liver suppression, endogenous wind calmness, spasm alleviation, blood circulation improvement and blood stasis elimination, evil wind dispelling of channel, and heart tranquilization and nourishment, and has satisfied curative effect on treating stubborn spasm of eye and facial muscles. The present invention has the characteristics of quick recovery and outstanding curative effect, and also has the characteristic that the preparation treats both outward symptoms and root causes of diseases; verified by the clinical observation of thousands of cases, the cure rate of the Chinese medicament is more than 90%. The Chinese medicament is prepared into capsules by treating the materials in the steps of proportioning, cleaning, selecting, crushing, sieving, mixing and encapsulating, and has the advantages of convenient administration and long-term storage.
The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.
The metabolism and hypoxia tolerance of marine ectotherms play key roles in limiting species geographical ranges, but underlying traits have only been directly measured for a small fraction of biodiversity. Here we diagnose and analyse spatial and phylogenetic patterns in hypoxia tolerance and its temperature sensitivity at ecologically active metabolic rates, by combining a model of organismal oxygen (O2) balance with global climate and biogeographic data for approximately 25 000 animal species from 13 phyla. Large-scale spatial trait patterns reveal that active hypoxia tolerance is greater and less temperature sensitive among tropical species compared to polar ones, consistent with sparse experimental data. Species energetic demands for activity vary less with temperature than resting costs, an inference confirmed by available rate measurements. Across the tree of life, closely related species share similar hypoxia traits, indicating that evolutionary history shapes physiological tolerances to O2 and temperature. Trait frequencies are highly conserved across phyla, suggesting the breadth of global aerobic conditions selects for convergent trait diversity. Our results support aerobic limitation as a constraint on marine habitat distributions and their responses to climate change and highlight the under-sampling of aerobic traits among species living in the ocean's tropical and polar oxythermal extremes. This article is part of the theme issue 'The evolutionary significance of variation in metabolic rates'.
The application provides a quantity-of-motion quantitative method based on a physical fitness index, which aims at customizing and adjusting the quantity of motion of a user through a series of steps so as to promote the physical health of the user. First, the current physical information and the physical health index of the individual are obtained from a database through the identity information provided by the user. Then, combining the exercise ability value and the historical physique data of the individual, calculating the basic exercise amount corresponding to the user by using a specific algorithm. In addition, historical motion data of the user is also obtained to help adjust the amount and combination of motions. The effective motion quantity is obtained by collecting the actual motion data of the user and then utilizing a motion analysis algorithm, and the motion completion degree is calculated according to the effective motion quantity. Finally, the exercise capacity value is updated according to the exercise completion degree and the effective exercise amount, so that a personalized and gradually optimized exercise plan is realized, and the physical health level and exercise capacity of a user are improved.
The pre-test data from the students in the experimental group were collected in the first lesson via the Google form created using the "Personal Introduction Form", "Adults' Perception Scale on Breast Milk (ASAÖ)" and "Iowa Infant Nutrition Attitude Scale (IOWA)", and the first and The second will be sent to the students by the authors. The first question was asked, "Are you willing to participate in this research?" Those who say yes will read and fill out this form themselves. At the end of the 14-week course period, post-test data will be obtained using the same method.
Prodn. of xylitol, sorbitol, lactitol or maltitol comprises continuous catalytic hydrogenation of an aq. soln. of D-xylose, alpha -D-glucose, lactose or maltose at 40-80 deg C and 100-400 bar in a fixed-bed reactor contg. support-free catalyst pellets with a crush strength of 20-250 N and an internal surface area of 10-80 m<2>/g. The pellets comprise one or more Fe-gp metals and Gp VIa promoter metals. The catalyst pellets are prepd. by compressing the corresp. metal powders, are cylindrical or spherical, have a dia. of 3-7 mm, and have a smooth surface. The feed is a 15-45% sugar soln. with a pH of 3.5-8.5.
In vitro models that mimic the pathophysiology in vivo are important tools to study mechanisms of disease and assess the pharmacology and toxicity of drugs. In this work, we report the development of a novel model of intestinal inflammation. This model is based on the co-culture of intestinal epithelial Caco-2 cells and murine J774A.1 macrophages. The model is shown to mimic the intestinal barrier in both healthy and inflamed state. In the healthy state, without external stimulation, Caco-2 and J774A.1 cells were co-cultured in one system without affecting the barrier integrity of intestinal epithelial cells and without inducing release of cytokines from macrophages. To mimic the inflamed intestine, Caco-2 cells were primed with an optimised cytokine cocktail (TNF-⍺, IFN-γ and IL-1β) and J774A.1 cells were pre-exposed to lipopolysaccharide (LPS) and IFN-γ for 24 h before combining the two cell lines into co-culture. In these conditions, a significant disruption of the epithelial barrier and an increase in pro-inflammatory cytokine (TNF-⍺ and IL-6) levels released from macrophages were detected. The data also show that inflammation in the co-culture model was temporary and reversible upon the removal of the inflammatory stimulus. This new in vitro model could be a valuable tool for investigating the safety and efficacy of drugs in the context of intestinal inflammation and provides advantages over other reported co-culture models of intestinal inflammation in terms of cost and simplicity.
Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients with MELD 11-20 will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg. After demonstrating absence of side effects in this group, patients in MELD 21-28 will follow the same dose escalation regiment as the MELD 11-20 group.
There is an unmet clinical need for effective therapy of breast cancer that has metastasized to the brain. In this scenario, median survival is around 12 months using currently available therapeutic interventions. The majority of chemotherapy-based clinical trials have considered the presence of central nervous system metastasis an exclusion criterion due to the risk of toxicities, the inability of chemotherapeutic agents to cross the blood brain barrier, and the limited overall survival within this patient population.

The preclinical data regarding the safety and activity of bevacizumab in vascular endothelial growth factor(VEGF)-expressing tumors provide a good rationale for its study in patients with breast cancer with metastasis to the brain. Yano, et al. illustrated that tumor cell expression of VEGF messenger ribonucleic acid and protein directly correlated with angiogenesis and growth of brain metastasis in a nude mouse model. Transfecting the experimental cell lines known to produce visceral metastasis with an anti-sense VEGF-gene significantly reduced the incidence of brain metastasis. Kim, et al. illustrated that a murine model specific for brain metastases originating from breast cancer showed elevated expression of the angiogenic and permeability-inducing factor VEGF-A. The growth of the brain metastases in this model was attenuated by the addition of a VEGF-tyrosine kinase inhibitor via induction of apoptosis and decreased angiogenesis. VEGF has also been implicated in the development of brain edema, a significant source of the morbidity and mortality associated with brain metastasis. Enhanced levels of VEGF and its receptors have been reported in a murine model after induction of cortical ischemia. Finally, antagonism of VEGF was demonstrated to reduce both immediate and delayed volume of infarct.

The optimal dose of bevacizumab has been extensively studied in phase I trials alone and in combination with chemotherapy. The safe and effective dose has been established as 10 mg/kg q 14 days or 15 mg/kg Q 21 days. In addition to irinotecan and paclitaxel, it has been previously used in phase II/III settings in combination with capecitabine, vinorelbine, gemcitabine, and docetaxel. Phase III studies showed an overall survival advantage when bevacizumab was added to an irinotecan/Fluorouracil (5FU)-based regimen for metastatic colorectal cancer, and when added to weekly paclitaxel for metastatic breast cancer.
Individuals with OSA can experience up to 300 sleep disruptions each night, which may result in excessive daytime sleepiness (EDS), one of the most common symptoms of OSA. EDS can have serious consequences, including motor vehicle accidents, poor school performance, and work-related accidents and performance issues. The most common treatment for OSA is CPAP therapy. This involves wearing a mask over the nose while sleeping; air then flows through the mask into the nose to maintain a level of pressure that keeps the breathing passages open. CPAP therapy typically results in fewer sleep and breathing disruptions during the night, which may increase an individual's alertness levels during the day. The purpose of this study is to evaluate the relationship between severity of sleep-disordered breathing and daytime alertness levels in adults with and withoutout symptoms of OSA.

This study will involve three to five study visits over a 2- to 3-month period. During the first 3 days, participants will record their sleep habits in a diary and will wear a device that measures breathing, oxygen levels, and sleep position. All participants will then take part in a 1-night inpatient stay at the sleep center lab during which brain, eye, muscle, heart, and breathing activity will be monitored. Participants with a confirmed diagnosis of OSA will stay at the sleep lab one additional night for observation while using a CPAP machine. The following day, tests to measure alertness, ease of falling asleep, and sleepiness levels will be administered. Participants will then use the CPAP machine at home for 4-6 weeks; each machine will be set at an appropriate level for the participant, and will record breathing patterns and pressure. Participants will receive weekly phone calls for monitoring purposes. At the end of Week 4, participants will return to the sleep lab for one additional night of CPAP monitoring, followed by alertness and sleep testing. Those with severe OSA will use the CPAP machine at a newly adjusted level for 5 additional days and return for repeat testing. All participants who have been compliant with CPAP will return to the lab for overnight sleep testing without the CPAP machine and for alertness testing.
Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could apply to human cell differentiation and for gene and cell-based therapies.
The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (Le., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues.  Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) formerly referred to as arrhythmogenic right ventricular dysplasia (ARVD) is a familial hetergenous clinical and molecular disease characterized by dilatation and dysfunction of the right ventricle and ventricular arrhythmias. The ventricular arrhythmias are heart rate and catecholamine dependent. Not infrequently, there is involvement of the left ventricle. The diagnosis of ARVC is critical as therapy including implantable defibrillators may prevent sudden death. However, identification of affected family members remains a major challenge due to limitation of current imaging and diagnostic techniques. We propose (1) to establish the sensitivity and specificity of the isoproterenol challenge test for ARVC by testing both patients with known ARVC and healthy volunteers; (2) to estimate the proportion of family members who present with incomplete criteria for ARVC but are subsequently diagnosed with the condition by an isoproterenol challenge test; and, (3) to study the inheritance of ARVC and the potential role of occult infection in its development.